<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044873</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-015</org_study_id>
    <nct_id>NCT03044873</nct_id>
  </id_info>
  <brief_title>Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin</brief_title>
  <official_title>Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to assess the effect of coadministration of multiple doses of BMS-986165 on the&#xD;
      systemic exposure of rosuvastatin in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Actual">March 27, 2017</completion_date>
  <primary_completion_date type="Actual">March 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum observed plasma concentration) of Rosuvastatin.</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Measured by plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-T) (Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration) of Rosuvastatin.</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Measured by plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(INF) (Area under the plasma concentration-time curve from time zero extrapolated to infinite time) of Rosuvastatin.</measure>
    <time_frame>Up to Day 13</time_frame>
    <description>Measured by plasma concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Deaths.</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
    <description>Measured by investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Serious Adverse Events.</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
    <description>Measured by investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Adverse Events.</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
    <description>Measured by investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events Leading to Discontinuation.</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
    <description>Measured by investigator assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Inflammatory Diseases</condition>
  <arm_group>
    <arm_group_label>BMS 986165 and Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.</description>
    <arm_group_label>BMS 986165 and Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.</description>
    <arm_group_label>BMS 986165 and Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent&#xD;
&#xD;
          2. Healthy male and female participants (not of childbearing potential) as determined by&#xD;
             no clinically significant deviation from normal in medical history, physical exam,&#xD;
             ECGs, and clinical laboratory determinations&#xD;
&#xD;
          3. Subjects with body mass index of 18 to 32 kg/m2, inclusive.&#xD;
&#xD;
          4. Women participants must have documented proof that they are not of childbearing&#xD;
             potential.&#xD;
&#xD;
          5. Men who are sexually active with WOCBP must agree to follow instructions for method(s)&#xD;
             of highly effective contraception for the duration of study treatment(s) plus 5&#xD;
             half-lives of BMS-986165 (4 days) plus 90 days (duration of sperm turnover) for a&#xD;
             total of 94 days of post BMS-986165 treatment. In addition, male participants must be&#xD;
             willing to refrain from sperm donation during this time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to BMS-986165, rosuvastatin, or related compounds, of myalgia or&#xD;
             rhabdomyolysis while taking rosuvastatin or related compounds or any other drug&#xD;
             allergy&#xD;
&#xD;
          2. Any significant acute or chronic medical illness, active TB requiring treatment or&#xD;
             documented latent TB within the previous 3 years, current or recent gastrointestinal&#xD;
             disease, current or recent history of nausea, vomiting, constipation or irregular&#xD;
             bowel movement&#xD;
&#xD;
          3. History of chronic headaches, syncope, orthostatic instability, or recurrent&#xD;
             dizziness, biliary disorders, drug-induced acne or rash, fibromyalgia, neutropenia or&#xD;
             thrombocytopenia&#xD;
&#xD;
          4. Smokers who currently smoke, recent drug or alcohol abuse, blood transfusion within 4&#xD;
             weeks of study treatment administration, current skin findings that could interfere&#xD;
             with the interpretation of study&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Phase I Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-986165</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

